Case Reports in Nephrology

Case Report

Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries

Table 4

Number and type of renal side effects for DOACs and antivitamin K retrieved (until 27^th April 2019) from VigiAccess database of the WHO Program for International Drug Monitoring (available at http://www.vigiaccess.org/).


	DOACs	AVKs
Total number of reported side effects	n = 235,457	n = 117,015

First case reported	2003	1968
Renal side effects, n (%)	7,725 (3.3)	2,145 (1.8)
Acute kidney injury	3,796 (49.1)	904 (42.1)
Renal failure unspecified	2,802 (36.3)	704 (32.8)
Renal hemorrhage	553 (7.2)	147 (6.9)
Chronic kidney disease	209 (2.7)	75 (3.5)
Tubulointerstitial nephritis	55 (0.7)	36 (1.7)

Results are presented as number of subjects (valid percentage). DOACs, direct oral anticoagulants; AVKs, antivitamin K. All DOACs include rivaroxaban, apixaban, edoxaban, and dabigatran. Acenocoumarol, warfarin, and phenprocoumone were regrouped as AVKs.